halobetasol propionate
Selected indexed studies
- Halobetasol propionate for the management of psoriasis. (Cutis, 2020) [PMID:32186526]
- A critical review of halobetasol propionate foam (0.05%) as a treatment option for adolescent plaque psoriasis. (Expert Rev Clin Immunol, 2022) [PMID:35930002]
- Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate. (J Am Acad Dermatol, 1991) [PMID:1757603]
_Worker-drafted node — pending editorial review._
Connections
halobetasol propionate is a side effect of
Sources
- Halobetasol propionate for the management of psoriasis. (2020) pubmed
- A critical review of halobetasol propionate foam (0.05%) as a treatment option for adolescent plaque psoriasis. (2022) pubmed
- Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate. (1991) pubmed
- Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. (2020) pubmed
- Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits. (2021) pubmed
- Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults. (2020) pubmed
- Halobetasol Propionate 0.01% Lotion for Plaque Psoriasis and Corticosteroid-Responsive Dermatoses. (2022) pubmed
- PMID:33570887 (2020) pubmed
- Resolving Hyperkeratotic Psoriasis: Mechanisms of Action and Additive Effects of Fixed-Combination Halobetasol Propionate and Tazarotene. (2025) pubmed
- PMID:33591679 (2020) pubmed